文献速递结核与非结核分枝杆菌医院感染防控

卡介苗百年:保护、非特异性获益与免疫受损宿主风险

100 years of Mycobacterium bovis bacille Calmette-Guérin.
PubMed 文献 · Lancet Infect Dis · 2021-09-07

综述回顾BCG百年应用:1921年首次用于新生儿,至今仍是唯一获批的人用结核疫苗。BCG对儿童粟粒性和脑膜结核提供持久强保护,但对肺结核尤其成人效果较弱;近二十年证据提示其对新生儿和老年人非结核感染有非特异性获益,并在非肌层浸润性膀胱癌有免疫治疗获益。作为减毒活疫苗,免疫受损宿主可发生局部或播散性感染,膀胱内灌注治疗膀胱癌后亦可发生。

要点

  • BCG对儿童粟粒性和脑膜结核保护强而持久,对肺结核尤其成人效果较弱。
  • BCG对新生儿和老年人非结核感染有非特异性获益,并用于非肌层浸润性膀胱癌免疫治疗。
  • 免疫受损宿主可发生BCG局部或播散性感染,膀胱内灌注后亦可发生。

核心结论

  • BCG仍是唯一获批的人用结核疫苗,百年应用挽救了数千万生命并接种人数超过任何其他疫苗。
  • BCG对儿童粟粒性和脑膜结核保护强而持久,但对肺结核尤其成人效果较弱。
  • BCG对新生儿和老年人非结核感染有非特异性获益,并在某些恶性肿瘤如非肌层浸润性膀胱癌有免疫治疗获益。
  • BCG作为减毒活疫苗可在免疫受损宿主引起局部或播散性感染,膀胱内灌注治疗膀胱癌后亦可发生。

研究设计与样本

  • 综述回顾BCG百年应用,涵盖1921年首次接种新生儿至现代证据。

主要发现

  • BCG对儿童粟粒性和脑膜结核提供持久强保护,对肺结核尤其成人效果较弱。
  • 近二十年证据提示BCG对新生儿和老年人非结核感染有非特异性获益。
  • BCG在非肌层浸润性膀胱癌等恶性肿瘤中提供免疫治疗获益。
  • BCG可在免疫受损宿主引起局部或播散性感染,膀胱内灌注后亦可发生。

关键数值与推荐

  • BCG仍是唯一获批的人用结核疫苗。
  • BCG对儿童粟粒性和脑膜结核保护强而持久,对肺结核尤其成人效果较弱。

临床怎么用

  • 应认识BCG对儿童重症结核的强保护作用,同时了解其对成人肺结核保护有限。
  • 对免疫受损宿主及接受膀胱内BCG灌注者,需警惕BCG局部或播散性感染。
  • BCG的非特异性获益支持其在新生儿和老年人中的潜在应用,但需权衡免疫受损宿主风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mycobacterium bovis bacille Calmette-Guérin (BCG), an experimental vaccine designed to protect cattle from bovine tuberculosis, was administered for the first time to a newborn baby in Paris in 1921. Over the past century, BCG has saved tens of millions of lives and has been given to more humans than any other vaccine. It remains the sole tuberculosis vaccine licensed for use in humans. BCG provides long-lasting strong protection against miliary and meningeal tuberculosis in children, but it is less effective for the prevention of pulmonary tuberculosis, especially in adults. Evidence mainly from the past two decades suggests that BCG has non-specific benefits against non-tuberculous infections in newborn babies and in older adults, and offers immunotherapeutic benefit in certain malignancies such as non-muscle invasive bladder cancer. However, as a live attenuated vaccine, BCG can cause localised or disseminated infections in immunocompromised hosts, which can also occur following intravesical installation of BCG for the treatment of bladder cancer. The legacy of BCG includes fundamental discoveries about tuberculosis-specific and non-specific immunity and the demonstration that tuberculosis is a vaccine-preventable disease, providing a foundation for new vaccines to hasten tuberculosis elimination.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Lange C, Aaby P, Behr MA, et al. 100 years of Mycobacterium bovis bacille Calmette-Guérin. Lancet Infect Dis. 2021. PMID: 34506734. doi:10.1016/S1473-3099(21)00403-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。